WO2000012512A1 - Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them - Google Patents
Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them Download PDFInfo
- Publication number
- WO2000012512A1 WO2000012512A1 PCT/GB1999/002864 GB9902864W WO0012512A1 WO 2000012512 A1 WO2000012512 A1 WO 2000012512A1 GB 9902864 W GB9902864 W GB 9902864W WO 0012512 A1 WO0012512 A1 WO 0012512A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- composition
- formula
- group
- phenyl
- Prior art date
Links
- 238000002428 photodynamic therapy Methods 0.000 title claims description 13
- 150000004033 porphyrin derivatives Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 373
- 238000000034 method Methods 0.000 claims abstract description 118
- 239000000203 mixture Substances 0.000 claims abstract description 102
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 63
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000002947 alkylene group Chemical group 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 39
- -1 C(0)N3 Chemical group 0.000 claims description 38
- 239000011701 zinc Substances 0.000 claims description 35
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 239000001301 oxygen Substances 0.000 claims description 33
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 27
- 229910052751 metal Inorganic materials 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 22
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 19
- 229910052725 zinc Inorganic materials 0.000 claims description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 16
- 229910052737 gold Inorganic materials 0.000 claims description 16
- 239000010931 gold Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 16
- 229910052752 metalloid Inorganic materials 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 229930002875 chlorophyll Natural products 0.000 claims description 12
- 235000019804 chlorophyll Nutrition 0.000 claims description 12
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 229930194542 Keto Natural products 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 11
- 125000000468 ketone group Chemical group 0.000 claims description 11
- ZFVPUXOTXTUDQH-UHFFFAOYSA-N phorbine Chemical compound N1C(C=C2N=C(C=C3NC4=C5CCC4=C3)C=C2)=CC=C1C=C1CCC5=N1 ZFVPUXOTXTUDQH-UHFFFAOYSA-N 0.000 claims description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 11
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 11
- 150000003568 thioethers Chemical class 0.000 claims description 11
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 10
- 229910000510 noble metal Inorganic materials 0.000 claims description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 9
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical group [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 9
- 125000006277 halobenzyl group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052710 silicon Inorganic materials 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 claims description 9
- 241001263180 Auriparus flaviceps Species 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 229910052732 germanium Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 208000037803 restenosis Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 125000002015 acyclic group Chemical group 0.000 claims description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 6
- 150000001414 amino alcohols Chemical class 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 208000008516 Capsule Opacification Diseases 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 238000002679 ablation Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000002357 endometrial effect Effects 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 238000009109 curative therapy Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 239000004945 silicone rubber Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 230000005292 diamagnetic effect Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 16
- 230000001419 dependent effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 66
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 35
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 125000005843 halogen group Chemical group 0.000 description 24
- 238000010992 reflux Methods 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002019 doping agent Substances 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 description 8
- JYPZLWCHCWLMEW-UHFFFAOYSA-N 12-(4-formylphenoxy)dodecyl acetate Chemical compound CC(=O)OCCCCCCCCCCCCOC1=CC=C(C=O)C=C1 JYPZLWCHCWLMEW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 7
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- VCRBUDCZLSQJPZ-UHFFFAOYSA-N porphyrinogen Chemical compound C1C(N2)=CC=C2CC(N2)=CC=C2CC(N2)=CC=C2CC2=CC=C1N2 VCRBUDCZLSQJPZ-UHFFFAOYSA-N 0.000 description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- RGZHEOWNTDJLAQ-UHFFFAOYSA-N 3,4,5-trihydroxybenzaldehyde Chemical compound OC1=CC(C=O)=CC(O)=C1O RGZHEOWNTDJLAQ-UHFFFAOYSA-N 0.000 description 6
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- 0 *Oc1ccc(C=O)cc1 Chemical compound *Oc1ccc(C=O)cc1 0.000 description 5
- VCBYAHWSOPQULH-UHFFFAOYSA-N 6-(4-formylphenoxy)hexyl acetate Chemical compound CC(=O)OCCCCCCOC1=CC=C(C=O)C=C1 VCBYAHWSOPQULH-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000006880 cross-coupling reaction Methods 0.000 description 5
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- VHNHAPCSMLJJDN-UHFFFAOYSA-N 3,4,5-trihexadecoxybenzaldehyde Chemical compound CCCCCCCCCCCCCCCCOC1=CC(C=O)=CC(OCCCCCCCCCCCCCCCC)=C1OCCCCCCCCCCCCCCCC VHNHAPCSMLJJDN-UHFFFAOYSA-N 0.000 description 4
- XYCUVMLGUDIETM-UHFFFAOYSA-N 3,4,5-trihexoxybenzaldehyde Chemical compound CCCCCCOC1=CC(C=O)=CC(OCCCCCC)=C1OCCCCCC XYCUVMLGUDIETM-UHFFFAOYSA-N 0.000 description 4
- IYPQNHOFBMQJFX-UHFFFAOYSA-N 3,4,5-tris-decoxybenzaldehyde Chemical compound CCCCCCCCCCOC1=CC(C=O)=CC(OCCCCCCCCCC)=C1OCCCCCCCCCC IYPQNHOFBMQJFX-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 125000003158 alcohol group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 3
- CCEUALYANSBISK-UHFFFAOYSA-N 16-(4-formylphenoxy)hexadecyl acetate Chemical compound CC(=O)OCCCCCCCCCCCCCCCCOC1=CC=C(C=O)C=C1 CCEUALYANSBISK-UHFFFAOYSA-N 0.000 description 3
- UDQPWHRXANOQTB-UHFFFAOYSA-N 3,5-didecoxybenzaldehyde Chemical compound CCCCCCCCCCOC1=CC(OCCCCCCCCCC)=CC(C=O)=C1 UDQPWHRXANOQTB-UHFFFAOYSA-N 0.000 description 3
- HAQLHRYUDBKTJG-UHFFFAOYSA-N 3,5-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=CC(C=O)=C1 HAQLHRYUDBKTJG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920005573 silicon-containing polymer Polymers 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 3
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 2
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- RHQWOQGUSSPMCZ-UHFFFAOYSA-N 3,5-dihexadecoxybenzaldehyde Chemical compound CCCCCCCCCCCCCCCCOC1=CC(OCCCCCCCCCCCCCCCC)=CC(C=O)=C1 RHQWOQGUSSPMCZ-UHFFFAOYSA-N 0.000 description 2
- HQBKKYBDXNROMS-UHFFFAOYSA-N 3,5-dihexoxybenzaldehyde Chemical compound CCCCCCOC1=CC(OCCCCCC)=CC(C=O)=C1 HQBKKYBDXNROMS-UHFFFAOYSA-N 0.000 description 2
- VGAAPMRNBKXZMA-UHFFFAOYSA-N 4-(12-hydroxydodecoxy)benzaldehyde Chemical compound OCCCCCCCCCCCCOC1=CC=C(C=O)C=C1 VGAAPMRNBKXZMA-UHFFFAOYSA-N 0.000 description 2
- FLMFLCHQUHATED-UHFFFAOYSA-N 4-(16-hydroxyhexadecoxy)benzaldehyde Chemical compound OCCCCCCCCCCCCCCCCOC1=CC=C(C=O)C=C1 FLMFLCHQUHATED-UHFFFAOYSA-N 0.000 description 2
- YCKLLCWNZUJZHZ-UHFFFAOYSA-N 4-(6-hydroxyhexoxy)benzaldehyde Chemical compound OCCCCCCOC1=CC=C(C=O)C=C1 YCKLLCWNZUJZHZ-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- ASIDMJNTHJYVQJ-UHFFFAOYSA-N bromo-dodecanol Chemical compound OCCCCCCCCCCCCBr ASIDMJNTHJYVQJ-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- GHLKSLMMWAKNBM-UHFFFAOYSA-N dodecane-1,12-diol Chemical compound OCCCCCCCCCCCCO GHLKSLMMWAKNBM-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000886 photobiology Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GOCYQQKRJUGVRU-UHFFFAOYSA-M sodium;but-2-enoate Chemical compound [Na+].CC=CC([O-])=O GOCYQQKRJUGVRU-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001429 visible spectrum Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- ORGPMZWSTKVIJI-UHFFFAOYSA-N zinc;cyclohexane Chemical compound [Zn+2].C1CC[CH-]CC1.C1CC[CH-]CC1 ORGPMZWSTKVIJI-UHFFFAOYSA-N 0.000 description 2
- 125000006834 (C4-C20) alkylene group Chemical group 0.000 description 1
- 125000006733 (C6-C15) alkyl group Chemical group 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- ZJJATABWMGVVRZ-UHFFFAOYSA-N 1,12-dibromododecane Chemical compound BrCCCCCCCCCCCCBr ZJJATABWMGVVRZ-UHFFFAOYSA-N 0.000 description 1
- CZZZWEDUOMBCQE-UHFFFAOYSA-N 1-bromoundec-1-ene Chemical compound CCCCCCCCCC=CBr CZZZWEDUOMBCQE-UHFFFAOYSA-N 0.000 description 1
- YPLVPFUSXYSHJD-UHFFFAOYSA-N 11-bromoundec-1-ene Chemical compound BrCCCCCCCCCC=C YPLVPFUSXYSHJD-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- FCMCSZXRVWDVAW-UHFFFAOYSA-N 6-bromo-1-hexanol Chemical compound OCCCCCCBr FCMCSZXRVWDVAW-UHFFFAOYSA-N 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- TZBKALOGIOQGBE-UHFFFAOYSA-N C(CCCCC)OC=1C=C(C=C(C=1OCCCCCC)OCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2 Chemical compound C(CCCCC)OC=1C=C(C=C(C=1OCCCCCC)OCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2 TZBKALOGIOQGBE-UHFFFAOYSA-N 0.000 description 1
- MKWYFTVWURNZCH-UHFFFAOYSA-N C(CCCCCCCCC)OC=1C=C(C=C(C1)OCCCCCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2 Chemical compound C(CCCCCCCCC)OC=1C=C(C=C(C1)OCCCCCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2 MKWYFTVWURNZCH-UHFFFAOYSA-N 0.000 description 1
- OEAGDEYNLUESGA-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC=1C=C(C=C(C=1OCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2 Chemical compound C(CCCCCCCCCCCCCCC)OC=1C=C(C=C(C=1OCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCC)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2 OEAGDEYNLUESGA-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016675 Filariasis lymphatic Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010061201 Helminthic infection Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 208000037263 Lymphatic filariasis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 229910007339 Zn(OAc)2 Inorganic materials 0.000 description 1
- MOFINMJRLYEONQ-UHFFFAOYSA-N [N].C=1C=CNC=1 Chemical group [N].C=1C=CNC=1 MOFINMJRLYEONQ-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000001672 corrected emission spectrum Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 208000005239 filarial elephantiasis Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GJBXIPOYHVMPQJ-UHFFFAOYSA-N hexadecane-1,16-diol Chemical compound OCCCCCCCCCCCCCCCCO GJBXIPOYHVMPQJ-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000006713 insertion reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002103 nanocoating Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000012704 polymeric precursor Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 239000013545 self-assembled monolayer Substances 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to compounds, compositions, apparatus and methods for treating a medical condition for which a photodynamic compound is indicated, particularly in the curative or prophylactic treatment of medical conditions such as atherosclerosis, cataracts, restenosis, secondary cataracts, endometrial ablation, bladder cancer, other cancers and proliferative diseases, inflammation and infection.
- Photodynamic therapy is a method of treating a diseased tissue of a patient.
- the surgical procedure involves administering a photodynamic agent to a patient, such as via an intravenous injection, and then irradiating the target diseased tissue with a separate light source.
- the photodynamic agent following irradiation with light emits reactive oxygen species, such as singlet oxygen, which disrupt the surrounding cellular tissue.
- US Patent No. 5594136 relates to texaphyrins supported on a matrix.
- the matrix-supported texaphyrins may be used in the separation of neutral and anionic species, in applications concerning phosphate ester hydrolysis, magnetic resonance imaging and photodynamic therapy.
- US Patent No. 5284647 relates to meso-tetraphenylporphyrin compounds which have a maximum of two substituents on the phenyl rings.
- the present invention therefore seeks to provide improved compounds, compositions, apparatus and methods for treating a medical condition where photodynamic therapy is indicated and open the way for medical conditions which are not currently treated by photodynamic therapy.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 independently represent H, lower alkyl, lower alkenyl and lower alkynyl, the latter three of which are optionally substitoted or terminated by one or more substitoents selected from halo, cyano, nitro, lower alkyl, OR 10 , C(0)R ⁇ , C(0)OR 12 , C(0)NR 13 R 14 and NR 15 R 16 ;
- M represents a metallic element or a metalloid element
- Each Y 1 , Y 2 and Y 3 is independently absent or represents O;
- Z is absent or represents lower alkylene
- R 10 , R 11 , R 12 , R 13 , R 14 , and R 16 independently represent H or lower alkyl
- R 15 represents H, lower alkyl, aryl or lower alkylaryl
- R 17 , R 18 and R 19 independently represent H, lower alkyl, aryl or lower alkylaryl
- R 20 represents H, lower alkyl, lower alkenyl or C(0)R 21 where R 21 represents an activating group for reaction to form an amide bond such as N-hydroxysuccinimide, N-hydroxybenzotriazole, or pentafluorophenyl ester; and
- lower alkyl is intended to include linear or branched, cyclic or acyclic, C r C 20 alkyl which may be interrupted by oxygen (preferably no more than five oxygen atoms are present in each alkyl chain).
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 22 and R 23 may represent include C r C 18 alkyl, C r C 17 alkyl, C r C 16 alkyl, C r C 15 alkyl, C 2 -C 15 alkyl, C 3 -C 15 alkyl, C 4 -C 15 alkyl, C 5 -C 15 alkyl, C 6 -C 15 alkyl, C 7 -C 15 alkyl, C 8 -C 15 alkyl, C 8 -C 14 alkyl, C 8 -C 12 alkyl and C 8 -C 10 alkyl.
- Preferred lower alkyl groups which R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R u , R 12 , R 13 , R 14 , R 15 , R 16 , R 20 and R 23 may represent include C 6 , C 7 , C 8 , C 9 , C 10 , C ⁇ , C 12 , C 13 , C 14 , C 15 and C 16 alkyl.
- Preferred lower alkyl groups which R 17 , R 18 and R 19 may represent include C r C 3 alkyl, especially methyl or ethyl.
- lower alkenyl and lower alkynyl are intended to include linear or branched, cyclic or acyclic, C 2 -C 20 alkenyl and C 2 -C 20 alkynyl, respectively, each of which may be interrupted by oxygen (preferably no more than five oxygen atoms are present in each alkenyl or alkynyl chain).
- lower alkenyl also includes both the cis and trans geometric isomers.
- Lower alkenyl groups which R 1 , R 2 , R 3 , R ⁇ R 5 , R 6 , R 7 , R 8 , R 9 , R 20 and R 23 may represent include C 2 -C 18 alkenyl, C 2 -C 17 alkenyl, C 2 -C 16 alkenyl, C 2 -C 15 alkenyl, C 3 -C 15 alkenyl, C 4 -C 15 alkenyl, C 5 -C 15 alkenyl, C 6 -C 15 alkenyl, C 7 -C 15 alkenyl, C 8 -C 15 alkenyl, C 8 -C 13 alkenyl and C 8 -C 12 alkenyl, C 8 -C 10 alkenyl.
- Preferred lower alkenyl groups which R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 20 , and R 23 may represent include C 6 , C 7 , C 8 , C 9 , C 10 , C ⁇ , C 12 , C 13 and C 14 alkenyl, especially C 10 alkenyl.
- Lower alkynyl groups which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 20 and R 23 may represent include C 2 -C 18 alkynyl, C 2 -C 17 alkynyl, C 2 -C 16 alkynyl, C 2 -C 15 alkynyl, C 2 -C 14 alkynyl, C 3 -C 15 alkynyl, C 4 -C 15 alkynyl, C 5 -C 15 alkynyl, C 6 -C 15 alkynyl, C 7 -C 15 alkynyl, C 8 -C 15 alkynyl, C 8 -C 14 alkynyl, C 8 -C 13 alkynyl, C 8 -C 12 alkynyl and C 8 -C 10 alkynyl.
- Preferred lower alkynyl groups which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 20 and R 23 may represent include C 6 , C 7 , C 8 , C 9 , C 10 , C n , C 12 , C 13 and C 14 alkynyl, especially C 10 alkynyl.
- lower alkylene also includes linear or branched C, to C 20 alkylene which may be interrupted by oxygen (preferably no more than five oxygen atoms are present in each alkenyl chain).
- Preferred lower alkylene groups which Z, V and S may represent include C 2 -C 20 alkylene, C 4 -C 20 alkylene, C 4 -C 18 alkylene, C 4 -C 16 alkylene, C 5 -C 16 alkylene, C 6 -C 16 alkylene, C 7 -C 16 alkylene, C 8 -C 16 alkylene, C 9 -C 16 alkylene, C l0 -C 16 alkylene, C 12 -C 16 alkylene and C 14 -C 16 alkylene.
- lower alkylene represents an alkylene having an even number of carbon atoms, for example C 2 , C 4 , C 6 , C 8 , C 10 , C 12 , C 14 , C 16 , C 18 and C 20 alkylene, especially C 6 , C 10 , C 12 , C 14 , C 16 and C 20 alkylene.
- aryl includes six to ten-membered carbocyclic aromatic groups, such as phenyl and naphthyl, which groups are optionally substitoted by one or more substituents selected from halo, cyano, nitro, lower alkyl, OR 10 , C(0)R n , C(0)OR 12 , C(0)NR 13 R 14 and NR 15 R 16 .
- the term "metallic element” is intended to include a divalent or trivalent metallic element.
- the metallic element is diamagnetic. More preferably, the metallic element is selected from Zn (II), Cu (II), La (III), Lu (III), Y (III), In (III) Cd (II), Mg (II), Al(lT ⁇ ) and Ru. Most preferably, the metallic element is Zn (II) or Mg (IT).
- metal is intended to include an element having physical and chemical properties, such as the ability to conduct electricity, that are intermediate to those of both metals and non-metals.
- metalloid element includes silicon (Si) and germanium (Ge) atoms which are optionally substitoted with one or more ligands.
- metallic element and metalloid element include a metal element or a metalloid element having a positive oxidation state, all of which may be substitoted by one or more ligands selected from halo, OH, OR 23 wherein R 23 is lower alkyl, lower alkenyl, lower alkynyl, aryl or alkylaryl as defined above.
- the term when X represents "S-] 2 " means the disulphide dimer, for example the disulphide dimer of the compound of formula I or the disulphide dimer of a photosensitizable compound as defined hereinafter.
- the compound of formula I or the photosensitizable compound is then bonded through the sulphur atom to an insoluble support thus fomiing a thio ether or a disulphide linkage.
- X represents "C(0)] 2 0" means the anhydride, for example the anhydride of the compound of formula I, the anhydride of an insoluble support or an anhydride of a photosensitizable compound as defined hereinafter.
- Preferred compounds of the invention include those in which each Y 1 , Y 2 and Y 3 represents oxygen, or each Y 1 and Y 3 represents oxygen and each Y 2 is absent.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent lower alkyl and each Y 1 , Y 2 and Y 3 represents oxygen, or each Y 1 and Y 3 represents oxygen and each Y 2 is absent and one or more of R 1 , R ⁇ R 4 , R 6 , R 7 and R 9 (preferably all) represent lower alkyl and R 2 , R 5 and R 8 (preferably all) represent H.
- Preferred compounds of the invention include those wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 independently represent H or lower alkyl;
- M represents a metallic element, a silicon atom, or a germanium atom
- Each Y 1 , Y 2 and Y 3 represents oxygen, or each Y 1 and Y 3 represents oxygen and each Y 2 is absent;
- Z is absent or represents lower alkylene.
- More preferred compounds of the invention include those wherein:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 independently represent linear or branched, cyclic or acyclic, C 6 -C 16 alkyl and each Y 1 , Y 2 and Y 3 represents oxygen; or
- R 1 , R 3 , R 4 , R 6 , R 7 and R 9 independently represent linear or branched, cyclic or acyclic, C 6 -C 16 alkyl, R 2 , R 5 and R 8 represent H, each Y 1 and Y 3 represents oxygen and each Y 2 is absent;
- M represents Zn (II), La (III), Lu (III), Y (III), In (III), Cd (II), Mg (II),
- Z represents lower alkylene having an even number of carbon atoms.
- Particularly preferred compounds of the invention include those wherein
- R 1 , R 2 , R 3 , R ⁇ R 5 , R 6 , R 7 , R 8 and R 9 independently represent, n-C 6 H 13 , n- C 8 H 17 , n-C 10 H 21 , n-C 12 H 25 , n-C 14 H 29 , or n-C 16 H 33 and each Y 1 , Y 2 and Y 3 represents oxygen; or R 1 , R 3 , R 4 , R 6 , R 7 and R 9 independently represent n-C 6 H 13 , n-C 8 H 17 , n-C 10 H 21 , n-C 12 H 25 , n-C 14 H 29 , or n-C 16 H 33 , R 2 , R 5 and R 8 represent H, each Y 1 and Y 3 represents oxygen and each Y 2 is absent;
- M represents Zn (II) or Mg (II);
- Z represents n-C 6 H 12 , n-C 8 H 16 , n-C 10 H 20 , n-C 12 H 24 , n-C 14 H 28 , n-C 16 H 32 , n-
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent n-C 6 H 13 , n-C 10 H 21 or n-
- R 1 , R 3 , R 4 , R 6 , R 7 and R 9 independently represent n-C 6 H 13 , n-C ⁇ 0 H 21 or n-
- M represents Zn (II) or Mg (II);
- Z represents n-C 6 H 12 , n-C 10 H 20 , n-C 12 H 24 , n-C 16 H 32 , (CH 2 ) 12 -(CH 2 ) 2
- Most preferred compounds of the invention include the compounds of Examples 67 to 81 described hereinafter.
- the reduction may be accomplished using methods which are well known to those skilled in the art.
- the reduction may be accomplished with a mixture of potassium hydroxide, an aryl sulphonylhydrazide, such as -toluenesulphonylhydrazide, and pyridine at a temperatore of between 80 °C to 110°C, preferably a temperature of 100°C to 105°C (R Bonnett et al, Biochem J. (1989) 261, p277-280).
- the reaction is performed using an appropriate metal salt, such as magnesium perchlorate or zinc acetate, in a suitable solvent (E Dietel et al, Journal of the Chemical Society, Perkin Transactions II, 1998, p 1357 to 1364.
- an appropriate metal salt such as magnesium perchlorate or zinc acetate
- the reaction may be performed using an anhydrous zinc salt such as Zn(OAc) 2 or ZnCl 2 in anhydrous tetrahydrofuran at reflux temperature of the reaction.
- a compound of formula II may be prepared by conversion of the Z-F functional group of a compound of formula III:
- reaction may be accomplished via formation of an isothiuronium salt, from a compound of formula III when F represents OH, using reagents and conditions which are well known to those skilled in the art (see I Chambrier et al., Synthesis, 1995, pl283 to 1286).
- the Z-OH alcohol functionality group of a compound of formula III is first derivatised into a Z-OS0 2 R 22 group, wherein R 22 is lower alkyl or phenyl, both of which may be optionally substitoted by one or more substitoents selected from halo, cyano, nitro, lower alkyl, OR 10 , C(0)R ⁇ , C(0)OR 12 , C(0)NR 13 R 14 and NR 15 R 16 , using methods which are well known to those skilled in the art.
- the Z-OH alcohol functionality compound of formula III may be mesylated by reaction with MeS0 2 Cl in an appropriate solvent, such as dichloromethane, at a temperatore of 10°C to 30°C.
- the resultant mesylate group may then be displaced by reaction with thiourea to form an isothiouronium salt.
- the reaction is performed in THF/ethanol solvent mixture which has optionally been deoxygenated, under reflux in the dark, preferably under an inert atmosphere of nitrogen.
- a compound of formula II when X represents SH may be prepared by the basic hydrolysis of the thiouronium salt in a THF/ethanol solvent mixture, for example using aqueous sodium hydroxide, under reflux and under an inert atmosphere, such as a nitrogen atmosphere.
- a compound of formula II when X represents S-] 2 may be prepared by the basic hydrolysis of the thiouronium salt in a THF/ethanol solvent mixture, for example using aqueous sodium hydroxide, at reflux temperatore of the reaction mixture under an oxygen atmosphere.
- the reaction may be accomplished via conversion of the Z-OH alcohol functionality group of a compound of formula III into a Z-OS0 2 R 22 group, wherein R 22 is as previously defined.
- the Z-OH alcohol functionality of the compound of formula III may be mesylated by reaction with MeS0 2 Cl.
- the resultant mesylate group may then be displaced by reaction with the appropriate alkenoate, for example sodium butenoate, in an appropriate organic solvent such as THF under reflux.
- a compound of formula III may be prepared by reaction of four molar equivalents of pyrrole with one molar equivalent of a compound of formula V:
- the reaction is carried out under acidic conditions by methods known to those skilled in the art (R G Little et al, Journal of Heterocyclic Chemistry, 1975, Vol 12, p343).
- an appropriate solvent such as an organic acid for example propionic acid
- a mineral acid such as hydrochloric, hydrobromic, hydroiodic, or sulphuric acid
- a Lewis acid such as zinc chloride or aluminium trichloride
- the compounds of formula V may be prepared from reaction of a compound of formula IX: IX
- the reaction is performed in a suitable organic solvent, such as methyl ethyl ketone or dichloromethane, under basic conditions, for example by using K 2 C0 3 , Na 2 C0 3 , pyridine or triethylamine, optionally at reflux temperatore of the reaction mixture.
- a suitable organic solvent such as methyl ethyl ketone or dichloromethane
- W represents OH
- a suitable organic solvent such as dry tetrahydrofuran (THF) in the presence of triphenylphosphine and an azodicarboxylate, for example diisopropyl-azo dicarboxylate).
- THF dry tetrahydrofuran
- the compounds of formula VI, VII, and VIII may be prepared from reaction of a compound of formula X:
- Y 1 , Y 2 and Y 3 are as previously defined before for a compound of formula III, or a suitably mono- or di-protected phenol derivative thereof, with a compound of formula R ! W, R 2 W, R 3 W, R 4 W, R 5 W, R 6 W, R 7 W, R 8 W or R ⁇ wherein R 1 , R 2 , R ⁇ R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as previously defined for a compound of formulae VI, VII and VIII, respectively, and W is a leaving group, such as halo.
- the reaction is performed in a suitable organic solvent, such as methyl ethyl ketone or dichloromethane, under basic conditions, for example by using K 2 C0 3 , Na 2 C0 3 , pyridine or triethylamine, optionally at reflux temperatore of the reaction mixture.
- a suitable organic solvent such as methyl ethyl ketone or dichloromethane
- the present invention provides a composition comprising an insoluble support and a compound of the invention of formula I.
- the insoluble support is also biocompatible.
- insoluble we mean that the support does not dissolve or decompose in aqueous solution under normal physiological conditions over the intended timescale for photodynamic ability (ie reactive oxygen species production) of the photosensitizable compound.
- the timescale would be relatively short for an insertable/removable medical device for example 1 to 180 minutes, or many years for semi-permanent or permanent implanted medical devices.
- biocompatible we mean that the support is in a form that does not produce an adverse, allergic or other untoward reaction when administered to a human or animal in accordance with the invention.
- the insoluble support enables the composition of the invention to be administered to a patient directly to the disease site without the need for administration by injection. This avoids the necessity for the photosensitizable compound to reach and accumulate at the target site, as is necessary with conventional photodynamic therapy, because the device is applied directly to the target site. Furthermore, the insoluble support eli ⁇ iinates or substantially reduces the dispersal and accumulation of the photosensitizable compound in non- target tissues, thereby minimising chemical toxicity and damage to healthy non-target tissue following irradiation with light of the appropriate wavelength or indeed from activation by sunlight and other environmental light sources. Moreover, unless deliberately left in the body, when the support is subsequently withdrawn, no compound of the invention is left in the body.
- the solid support comprises polyethylene; polypropylene; polystyrene; poly acrylamide; poly amide; a resin for solid phase oligopeptide and/or oligonucleotide synthesis, such as a Merrifield resin; a natural or synthetic polysaccharide; a silicon derivative such as a functionalised silica, a glass, a silicone or a silicone rubber; an alumina; a noble metal, preferably a gold film optionally mounted on a glass surface; or a porous solid such as a controlled pore glass, a gel permeation material or a zeolite.
- a resin for solid phase oligopeptide and/or oligonucleotide synthesis such as a Merrifield resin
- a natural or synthetic polysaccharide such as a functionalised silica, a glass, a silicone or a silicone rubber
- an alumina a noble metal, preferably a gold film optionally mounted on a glass surface
- a porous solid such
- the insoluble support may be flexible, such as a flexible membrane, or a rigid support.
- the insoluble support is coated and/or impregnated with the photosensitizable compound. More preferably, the photosensitizable compound is fixed to the surface of the insoluble support, optionally via a covalent bond, and optionally includes a bifunctional spacer molecule to space the compound from the insoluble support.
- a compound fixed to the surface of the insoluble support may be represented by formula XI:
- R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 , A-B, C-D, M, Z, Y 1 , Y 2 and Y 3 are as previously defined for a compound of formula I;
- V is absent or represents lower alkylene or an alkylaryl group;
- IS represents the insoluble support;
- the group U of the insoluble support represents NHR 15 .
- the group U of the insoluble support represents C0 2 R 20 .
- the group U of the insoluble support represents Si(OR 17 ) 3 , SiR 18 (OR 17 ) 2 , SiR 18 R 19 (OR 17 ), Sihalo 3 , Sihalo 2 R 17 , or SihaloR 17 R 18 .
- the insoluble support includes a noble metal.
- composition of formula XI may also be represented by a compound of formula XII.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , Y 1 , Y 2 , Y 3 , Z, A-B, C-D and M are as previously defined for a compound of formula I
- IS represents the insoluble support
- V is absent or represents lower alkylene or an alkylaryl group
- E represents alkylene, ether, amide, silyloxy, alkynyl, alkenyl, thioether, NR 15 , (CH 2 CH 2 ⁇ ) m , keto, ester, or phenyl wherein m represents 1 to 10 and R 15 is as previously defined hereinbefore.
- a process for the preparation of a composition of formula XII which comprises reacting a compound of the invention of formula I as previously defined with a compound of formula XIII:
- IS - V- U XIII wherein IS, V and U are as defined above.
- the X groups present on a compound of the invention react with available groups, termed U, present on or previously inserted into, the insoluble support.
- the reactive U group of the insoluble support may be either initially present or introduced by semi-synthesis (for example from materials derived from natural sources) or by ab initio chemical synthesis.
- the photosensitizable compound may be linked to the polymeric support by using a dopant, such as an acrylic acid.
- a dopant such as an acrylic acid.
- the dopant may be incorporated into the polymeric support to provide a binding site for the photosensitizable compound or the dopant may be bonded to the photosensitizable compound and the resultant compound copolymerized with the polymeric support.
- Reagents such as carbodiimides, l ,l '-carbonyldiimidazole, cyanuric chloride, chlorotriazine, cyanogen bromide and glutaraldehyde, and processes such as use of mixed anhydrides, reductive amination and metal- assisted cross-couplings of halogenated compounds with organometallic compounds may also be used to couple the photosensitizable compound to the insoluble support.
- a composition for the in vivo delivery of a photosensitizable compound to a target tissue comprising a photosensitizable compound and a biocompatible insoluble support, wherein the photosensitizable compound comprises a macrocycle having at least four unsatorated five-membered nitrogen containing rings.
- the term "unsatorated five-membered nitrogen containing ring” includes pyrrole, dihydropyrrole, pyrroline and isomers thereof.
- the photosensitizable compound comprises a benzoporphyrin, a porphycene, a purpurin, an etiopurpurin, a chlorophyll, an haematoporphyrin, a phorbine, a chlorphyrin, a verdin, a bacteriochlorin, a porphyrinogen, a phthalocyanine, or a mixtore of any two or more of these, or a pharmaceutically acceptable derivative thereof.
- the photosensitizable compound is a porphycene, a purpurin, a chlorophyll, a phthalocyanine, or a benzoporphyrin or a derivative of any of these compounds.
- each of the four unsatorated five- membered nitrogen containing rings of the purpurin may be independently substituted with a lower alkyl, preferably an ethyl group.
- Each of the phenyl rings of the phthalocyanine may independently include a sulphate, amino, nitro, hydroxy, or carboxyl group.
- composition of the present invention comprising a photosensitizable compound and the insoluble support is preferably a compound of formula XIV:
- PC represents a photosensitizable compound comprising a benzoporphyrin, a porphycene, a purpurin, an etiopurpurin, a chlorophyll, an haematoporphyrin, a phorbine, a chlorphyrin, a verdin, a bacteriochlorin, a porphyrinogen, a phthalocyanine, or a mixture thereof
- IS represents the biocompatible insoluble support
- the group U of the insoluble support represents NHR 15 .
- the group U of the insoluble support represents C0 2 R 20 .
- the group U of the insoluble support represents Si(OR 17 ) 3 , SiR 18 (OR 17 ) 2 , SiR 18 R 19 (OR 17 ), Sihalo 3 , Sihalo 2 R 17 , or SihaloR 17 R 18 .
- the insoluble support includes a noble metal.
- the photosensitizable compound includes a spacer group S to which the X group is attached, wherein S represents lower alkylene or an alkylaryl group.
- the insoluble support includes a spacer group V to which the U group is attached, wherein V represents lower alkylene or an alkylaryl group.
- the photosensitizable compound includes a metallic or a metalloid element bonded to a nitrogen atom, preferably to a pyrrole nitrogen atom, of the photosensitizable compound.
- composition of the present invention comprising a photosentizable compound and the insoluble support may also be represented by a compound of formula XV.
- E represents alkylene, ether, amide, silyloxy, alkynyl, alkenyl, thioether, NR 15 , (CH 2 CH 2 0) m , keto, ester, or phenyl, wherein m represents 1 to 10 and R 15 is as previously defined hereinbefore.
- the present invention provides a process for the preparation of the composition of the invention comprising a photosensitizable compound and the insoluble support, which is preferably a compound of formula XIV or XV, as defined hereinbefore.
- the insoluble support is coated and/or impregnated with the photosensitizable compound. More preferably, the photosensitizable compound is fixed to the surface of the insoluble support, optionally via a covalent bond and optionally includes a bifunctional spacer molecule to space the photosensitizable compound from the insoluble support.
- the process for the preparation of a composition of the present invention comprises reacting a compound of formula XVI:
- PC-S-X together represents the photosensitizable compound
- X is as previously defined for a compound of formula XIV
- PC represents a benzoporphyrin, a porphycene, a purpurin, an etiopurpurin, a chlorophyll, an haematoporphyrin, a phorbine, a chlorphyrin, a verdin, a bacteriochlorin, a porphyrinogen, a phthalocyanine, or a mixtore of any two or more of these
- S is absent or represents lower alkylene or an alkylaryl group, with a compound of formula XVII:
- IS-V-U together represents the insoluble support
- U is as previously defined for a compound of formula XIV and V is absent or represents lower alkylene or an alkylaryl group.
- the X groups of the photosensitizable compound react with available groups, termed U, present on or previously inserted into, the insoluble support.
- the reactive X group of the photosensitizable compound and the reactive U group of the insoluble support may be either initially present or introduced by semi-synthesis (for example from materials derived from natural sources) or by ab initio chemical synthesis.
- the photosensitizable compound may be linked to the polymeric support by using a dopant, such as an acrylic acid.
- a dopant such as an acrylic acid.
- the dopant may be incorporated into the polymeric support to provide a binding site for the photosensitizable compound or the dopant may be bonded to the photosensitizable compound and the resultant compound copolymerized with the polymeric support.
- Reagents such as carbodiimides, l, -carbonyldiimidazole, cyanuric chloride, chlorotriazine, cyanogen bromide and glutaraldehyde, and processes such as use of mixed anhydrides, reductive amination and metal- assisted cross-couplings of halogenated compounds with organometallic compounds may also be used to couple the photosensitizable compound to the insoluble support.
- monomers such as plastics made from unsatorated monomers (ie polyethylene, polypropylene, polyacrylates, polystyrene, polyamide) by processes such as free radical induced polymerisation to give either rigid or flexible insoluble polymeric matrices incorporating the desired photos
- the photosensitizable compound when the photosensitizable compound represents a benzoporphyrin, a porphycene, a purpurin, a chlorophyll, an haematoporphyrin, an etiopurpurin, a phorbine, a verdin, a bacteriochlorin or a porphyrinogen having a group X representing C0 2 R 20 , the photosensitizable compound may be incorporated into a polymer having a NHR 15 group via amide bond formation by techniques which are well- known to those skilled in the art. Alternatively, the photosensitizable compound may be incorporated into a polymer having a carboxyl group by formation of a diamide type linkage using a bis-amino spacer.
- the photosensitizable compound when the photosensitizable compound represents a porphycene having a group X representing NHR 15 , then the photosensitizable compound may be incorporated into a polymer having a C0 2 R 20 group via amide bond formation by techniques which are well- known to those skilled in the art. Alternatively, the photosensitizable compound may be incorporated into a polymer having an amino group by formation of a urea type linkage.
- the photosensitizable compound when the photosensitizable compound is an haematoporphyrin, a phorbine or a porphyrinogen having a group X representing OH, then the photosensitizable compound may be incorporated into a functionalised silica group, such as a glass, by formation of a silyloxy linkage by methods well known to those skilled in the art.
- the photosensitizable compound when the photosensitizable compound is a phorbine or a bacteriochlorin having a group X representing SH, then the photosensitizable compound may be bonded through the sulphur atom to the surface of a noble metal, such as metallic gold, thus forming a thio ether or disulfide linkage by methods well known to those skilled in the art.
- a noble metal such as metallic gold
- monomers such as plastics made from unsatorated monomers (ie polyethylene, polypropylene, polyacrylates, polystyrene, polyamide) or the photosensitizable compound may be incorporated into a polymer having a halo, C ⁇ CH
- photosensitizable compound is derived from natural sources
- advantage may be taken, for instance, of vinyl or carboxyl groups that are present in the native compound.
- the isolation and/or synthesis of such photosensitizable compounds as previously defined for a compound of formula I are described for example in Bonnett R.
- these and other functionalities may also be introduced into the photosensitizable compound using the appropriate chemistry on suitably protected precursor molecules.
- carboxyl groups may be activated by conversion to the corresponding acid chloride, azide or activated ester and then incorporated into a construct by treatment with a polymeric matrix bearing nucleophilic substitoents.
- compositions of the present invention comprising a photosensitizable compound and the insoluble support, which is preferably a compound of formula XIV or XV, where the photosensitizable compounds are synthesised for incorporation into the insoluble support to form a construct:
- linkage of the photosensitizable compound to support matrices can be made through specific functional groups in multi-functional molecules.
- the precursors may be synthesised using methods such as standard peptide chemistry described in the literature, for example in Houben Weyl, Methoden der Organischen Chemie, Parts 1 and 2, Vol 15. If necessary the carboxyl, amino, hydroxyl or thio functionalities of the precursor molecules may be protected using suitable reversible protecting groups.
- protecting groups is fully described in "Protective Groups in Organic Chemistry” , edited by J W F McOmie, Plenum Press (1973), and “Protective Groups in Organic Synthesis", 2 nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).
- the protected precursor molecules may be condensed with spacer molecules such as natural amino acids or other linkers by methods well known to those skilled in the art to give mixtores of derivatised protected photosensitizable compounds (for subsequent covalent linkage to preformed polymeric supports) which are enriched in the desired photosensitizable compound by appropriate choice of the relative amounts of the precursors and the conditions of the condensation reaction.
- spacer molecules such as natural amino acids or other linkers
- the desired photosensitizable compound may be isolated by chromatographic separation or crystallisation. These procedures can be optimised by judicious choice of the groups R combined with reversible optional protection of the function in the side-chain, if appropriate. At this point it can be advantageous to insert the metal atom into the macrocycle.
- the functional group where appropriate, is activated or derivatised, and the macrocycle can be attached to a surface or copolymerised with a suitable comonomer. At various points in the sequence of reactions, it is possible to manipulate the photosensitizable compound structure when separation of any isomers is desired.
- compositions of the invention are photodynamic as they emit reactive oxygen species, such as singlet oxygen or oxygen free radicals, following irradiation with light of the appropriate wavelength in the presence of oxygen. Consequently, the compositions of the invention are suitable for use in the curative and/or prophylactic treatment of a medical condition for which a photodynamic agent is indicated.
- reactive oxygen species such as singlet oxygen or oxygen free radicals
- compositions of the invention are suitable for use in the curative and/or prophylactic treatment of atherosclerosis; cataracts; restenosis; secondary cataracts; endometrial ablation; cancers such as bladder cancer; other proliferative diseases; bacterial infections such as Gram-positive cocci (eg Streptococcus), Gram-negative cocci (eg Neisseria), Gram-positive bacilli (eg Corynebacterium species) Gram-negative bacilli (eg Escherichia coli) acid-fast bacilli (eg a typical Mycobacterium) and including infections causing abscesses, cysts, arthritis, urinary tract infections, pancreatitis, pelvic inflammatory disease, peritonitis, prostatitis, vaginal infections, ulcers and other localised infections; actinomyces infections; fungal infections such as Candida albicans, Aspergillus and Blastomyces; viral infections such as HIV, encephalitis, gastro-enteritis, hae
- the insoluble support is a noble metal film, preferably the noble metal is gold and the thickness of the film is 10 to 1000 nm.
- X in a compound of the invention of formula I or a photosensitizable compound of formula XVI may represent SH or S-] 2 .
- the compound of formula I or the photosensitizable compound is bonded through the sulphur atom to the surface of the metallic gold thus forming a thio ether or disulphide linkage.
- a noble metal film coated with a compound of the invention or a photosensitizable compound may be prepared by immersing the film in a solution of a compound of formula I, wherein X represents SH or S-] 2 , in a suitable solvent, such as hexane, chloroform or dichloromethane, at room temperatore for up to 24 hours, optionally with stirring.
- a suitable solvent such as hexane, chloroform or dichloromethane
- the insoluble support includes a glass surface and X in the compound of formula I or X in the photosensitizable compound of formula XVI may represent Si(halo) 3 , particularly Si(Cl) 3 .
- the photosensitizable compound is then bonded through the silicon atom to the glass surface
- compositions of the invention may be fabricated into or coated on various medical devices and surgical implants, such as balloon catheters, vascular stents, intraocular lenses, orthopaedic implants, other artificial surgical implants, interfaces, artificial joints, surgical screws and pins.
- medical devices such as balloon catheters, vascular stents, intraocular lenses, orthopaedic implants, other artificial surgical implants, interfaces, artificial joints, surgical screws and pins.
- Each of the medical devices may also optionally include an integrated light delivery system.
- a vascular stent is a permanent implant comprising a mesh-like tube which is used to maintain an open lumen within the blood vessels.
- a vascular stent is made from metal, stainless steel, nickel, platinum, all of which are optionally coated with a polymer to increase biocompatability.
- the stent may be made completely from polymers or plastics.
- the stent is delivered to the target site in a blood vessel with a guide catheter, usually after a patient has been administered a bolus of heparin.
- the guide catheter has a retractable sheath which shields the stent until it is at the target site.
- the sheath is retracted to expose the stent.
- the stent either self expands or it is expanded with an inflatable balloon of a balloon catheter. The stent delivery system, balloon and catheter are removed leaving the stent within the blood vessel.
- An intraocular lens is a lens that is adapted to be fixed to the periphery of the iris or an opening in the capsular bag of the eye.
- the lens is made from an acrylic polymer, such as polymethyl methacrylate or hydroxy ethyl methacrylate, optionally coated with a biocompatible polymer such as phosphorylcholine.
- a suitable intraocular lens (IOL) is described in US 5716364, which is incorporated herein by reference.
- the IOL is made of a polymeric material such as a polyolefin, for example polypropylene.
- the coating is a molecular monolayer that partially or totally coats the surface of the medical device.
- the coating may be fixed to the medical device by forming a bond between the -ZX functional group of the compound of the invention of formula I or a photosensitizable compound of formula XVI and the reactive U functional groups of the insoluble support as previously defined.
- the coating may be formed by reacting the compounds or compositions of the invention with the polymeric precursors of a medical device prior to formation of the medical device.
- the medical device when the medical device comprises a silica based polymer optionally having reactive or functionalised silica groups, such as a silicone polymer, the medical device also acts as the insoluble support and it may be coated and/or impregnated by direct reaction with a compound of the invention of formula I or a photosensitizable compound of formula XVI.
- the compound of the invention or the photosensitizable compound is bonded to the silicone polymer with one of the linkages as previously disclosed herein.
- the medical devices enable the compounds of the invention and the photosensitizable compounds to be delivered to a particular target tissue.
- the target cells are the smooth muscle cells on the blood vessel lumen surface, and inflammatory cells such as macrophages
- the target cells are the lens epithelial cells on the inner surface of the capsular bag which are typically aggregated around the periphery of the capsular bag.
- This site specific delivery reduces or substantially eliminates undesirable side-effects associated with photodynamic agents residing in and accumulating in non-target tissues.
- This increases patient compliance as a patient who has been treated with a medical device of the present invention only needs to shield the treated tissue from exposure to light, rather than other parts of the body which may be necessary with photodynamic agents having no site specific delivery system.
- the coating of the medical device emits reactive oxygen species, such as singlet oxygen, which travel a distance of between 50 nm and 5 nm (micrometers) from the device depending on the composition of the medium surrounding the device.
- reactive oxygen species such as singlet oxygen
- the medium is a biological tissue
- the reactive oxygen species travel between 10 and 50 nm from the device
- the reactive oxygen species travel approximately 1 to 5 ⁇ m from the device when the medium is a saline solution
- even greater distances 10 to 100 ⁇ m can be achieved in other liquids, alcohols, acetone and aqueous mixtores thereof.
- Each of the medical devices may also include a fluid delivery system for delivering desired medium to the coating of the device.
- a fluid delivery system for delivering desired medium to the coating of the device.
- the distance the reactive oxygen species emitted from the devices of the present invention may be controlled accurately. This further reduces the undesirable side-effects associated with reactive oxygen species interacting with non-target tissue and thereby further increases patient compliance.
- the material introduced into the body will be sterile and may also be non-pyrogenic. Sterility is typically achieved by conventional temperature, pressure, radiation or chemical sterilisation treatment techniques, preferably during the manufacture of the devices.
- the present invention provides methods for treating or preventing cataracts, secondary cataracts, bladder cancers, restenosis, atherosclerosis, endometrial ablation, other cancers and proliferative diseases, inflammation and infection using the medical devices of the invention.
- the present invention provides a method of producing light-induced singlet oxygen which comprises irradiating a compound or composition of the invention with light of the appropriate wavelength preferably 500 to 800 nm, in the presence of oxygen.
- Figure 1 is a longitudinal cross-section of a preferred balloon attached to a catheter.
- Figure 2 is a typical decay and fitted curve for the title compound of Example 78 in toluene excited at 355 nm using a pulse energy of 365 ⁇ J.
- Figure 3 is a plot showing the linear relationship between the singlet oxygen emission intensity and the laser energy for the title compound of Example 78 and meso-tetraphenyl porphyrin (TPP).
- Figure 1 shows a preferred embodiment of the invention comprising a balloon 1 having a surface coating 2 of a photodynamic compound or composition, an inflation port 3 and a two-way valve (not shown) to enable the balloon to be selectively inflated and deflated.
- the balloon is preferably made from an elastomeric material, such as a flexible silicone polymer, and the coating is fixed to the balloon with linkage as described herein before.
- the balloon is attached to a first end of a catheter 4.
- a second end of the catheter includes means for receiving a pressure controlled inflation device 5, such as a standard Luer pressure tight connector having a stopcock.
- the pressure controlled inflation device 5 is a normal syringe used in standard angioplastic and intraocular procedures with balloon catheters.
- the syringe has an accurate graduation for measuring the volume of fluid injected into the balloon. It may also be optionally fitted with a pressure gauge. In use, pressure and volume measurements enable the balloon to be fully inflated at the target site whilst reducing the risk of damaging the surrounding non-target healthy tissue.
- the first end of the catheter terminates in an injection means for filling the balloon with a filler material which is preferably a biocompatible fluid, such as sterile water.
- a filler material which is preferably a biocompatible fluid, such as sterile water.
- the catheter includes a fluid delivery system (not shown) for delivering a desired medium to the coating 2.
- a light source preferably a fibre optic cable 6, extends throughout the length of the catheter and into the interior of the balloon 1 terminating with means for distributing light 7 in the balloon.
- Air is removed from the apparatus before commencing the surgical operation by connecting the syringe, typically a 30ml syringe, to the Luer pressure tight connector, opening the stopcock and withdrawing the syringe piston.
- the stopcock is closed and the syringe removed. The apparatus is now ready for use.
- a pressure controlled inflation device preferably a 30ml syringe containing sterile water with no air bubbles and fitted with a pressure gauge, is attached to the luer fitting, the stopcock is opened and the balloon 1 inflated to a specific volume and/or pressure with the sterile water.
- the required volume/pressure for inflation of the balloon can be determined by routine trial and error testing by a skilled person.
- a light source is operated so that light of the appropriate wavelength, typically 500 to 800nm, passes through the fibre optic cable into the interior of the balloon.
- the coating 2 absorbs the light and emits singlet oxygen radicals in the vicinity of the balloon, typically within a radius of between 50nm and 5 ⁇ m from the balloon.
- the fluid delivery system may be used to deliver a desired fluid into the space 9 between the coating 2 and the target tissue 8, thereby enabling the user to vary and control the distance the singlet oxygen species are emitted from the balloon 1.
- the singlet oxygen radicals induce molecular and cellular destruction of the target tissue.
- Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an electrospray interface (FAB-MS).
- the matrix-assisted laser desorption/ionization mass spectra of the porphyrins were obtained using a dithranol matrix.
- FAB-MS spectra were obtained using a 3-nitrobenzyl alcohol (NOB A) matrix.
- NOB A 3-nitrobenzyl alcohol
- ⁇ -NMR spectra were measured at 60MHz on a Jeol JNM-PMX60 spectrometer, at 270MHz on a Jeol EX 270 spectrometer and at 300MHx on a Varian Gemini-300 spectrometer in CDC1 3 using TMS as an internal reference.
- Ultraviolet/visible spectra of solutions of compounds in tetrahydrofuran (THF) or toluene were measured using a Hitachi U-3000 spectrophotometer or a ATI-Unicam UV-2 spectrophotometer.
- Reflectance-absorbance infra red (RAIR) spectra were recorded on a BIO- RAD FTS 165 spectrophotometer.
- Fluorescence emission spectra were recorded using a Spex Fluorolog 3 spectrophotometer at an excitation wavelength of 355nm, emission at 550 to 800nm, with a bandpass of 2nm.
- the singlet oxygen quantum yields were determined by the direct measurement of singlet oxygen phosphorescence at 1270nm.
- Samples were excited using the third harmonic of a Q-s witched Nd:YAG (neodymium: yttrium-aluminium-garnet) Spectra Physics GCR-150-10 laser, operating at an excitation wavelength of 355nm.
- a small fraction of the laser output was passed through a solution state filter containing aqueous cobalt (II) sulphate (CoS0 4 ) to remove residual 532 and 1064nm radiation and then down a 8mm diameter liquid light guide (Oriel).
- II cobalt
- CoS0 4 8mm diameter liquid light guide
- the end of the light guide was held against a 1cm x 1cm fluorescence cuvette (Hellma) holding the sample.
- the incident laser energy for each measurement was determined using a pyroelectric detector held behind the sample. This detector was calibrated at the start of the experiment using a second calibrated energy meter (Gentec ED 100).
- the laser energy was adjusted by placing cells containing aqueous sodium nitrite between the CoS0 4 filter and the light guide. Typical pulse energies used were in the range of 25-500 ⁇ J per pulse. Shot to shot noise was estimated to be ⁇ 10% and sets of 20 shots gave an average value within ⁇ 3 % .
- Phosphorescence from the sample was collected and passed through an interference filter centred at 1270nm available from (Infra Red Engineering Ltd) and then focused onto the active area of a liquid nitrogen cooled germanium photodiode (North Coast EO-817P).
- the output from this device was AC coupled to a digital oscilloscope (Tektronix TDS-320) which digitised and averaged the transients. Typically 20 laser shots were used for each sample. The averaged data was transferred to a PC where it was stored and analysed.
- the title compounds of Examples 2 to 8 represent compounds of formula V
- the title compounds of Examples 9 to 14 represent compounds of formula VI, VII and VIII
- the title compounds of Examples 28 to 40 represent compounds of the formula III
- the title compounds of Examples 54 to 66 represent compounds of formula II
- the title compounds of Examples 67 to 81 represent compounds of formula I.
- 1,12-Dodecanediol 50g, 0.25mol
- hydrogen bromide 48% 220ml
- petroleum ether b.p. 80-100°C
- Example 6 from 4-(6-hydroxy-hexyloxy)-benzaldehyde (see Example 3 above). After addition of the reaction mixtore to water, the title compound was obtained as a yellow oil. The oil was extracted with diethyl ether, the etheral extract was washed with aqueous K 2 C0 3 , brine, and dried over MgS0 4 , filtered and the solvent removed under reduced pressure.
- Example 6 The title compound was prepared as described in Example 6 from 4-(16- hydroxy-hexadecyloxy)-benzaldehyde (see Example 4 above). The title compound was obtained as an oil.
- the solid reaction product was collected by filtration and washed with methyl ethyl ketone (Soxhlet). The filtrate was evaporated under reduced pressure to give the title compound as a red oil which was crystallised from acetone.
- Example 15 above from 3,4,5-trihexyloxy-benzaldehyde (see Example 10) acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 15 above from 3,4,5-trihexadecyloxy-benzaldehyde (see Example 11), acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 15 above from 3,4,5-tridecyloxy-benzaldehyde (see Example 9), acetic acid 16-(4-formyl-phenoxy)-hexadecyl ester (see Example 8) and pyrrole.
- Example 15 above from 3,5-dihexyloxy-benzaldehyde (see Example 12), acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 25 above from 3,5-dihexyloxy-benzaldehyde (see Example 12), acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 25 above from 3,5-dihexyloxy-benzaldehyde (see Example 12), acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 15 above from 3,5-didecyloxy-benzaldehyde (see Example 13), acetic acid 6-(4-formyl-phenoxy)-hexyl ester (see Example 7) and pyrrole.
- Example 24 above from 3,5-didecyloxy-benzaldehyde (see Example 13), acetic acid 12-(4-formyl-phenoxy)-dodecyl ester (see Example 6) and pyrrole.
- Example 28 above from 5-[4-(6-acetyloxy-hexyloxy)-phenyl]-10, 15,20- tris-(3,4,5-trihexyloxy-phenyl)-porphyrin (see Example 17).
- Example 28 above from 5-[4-(6-acetyloxy-hexyloxy)-phenyl]-10, 15,20- tris-(3,4,5-tridecyloxy-phenyl)-porphyrin (see Example 18).
- Example 28 above from 5-[4-(6-acetyloxy-hexyloxy)-phenyl]-10, 15,20- tris-(3,4,5-trihexadecyloxy-phenyl)-porphyrin (see Example 19).
- Example 28 above from 5-[4-(6-acetyloxy-hexyloxy)-phenyl]-10, 15,20- tris(3,5-didecyloxy-phenyl)-porphyrin (see Example 25).
- Example 41 above from 5-[4-(12-hydroxy-dodecyloxy)-phenyl]-10, 15,20- tris-(3,4,5-trihexyloxy-phenyl)-porphyrin (see Example 29).
- Example 41 above from 5-[4-(12-hydroxy-dodecyloxy)-phenyl]-10, 15,20- tris-(3,4,5-trihexyloxy-phenyl)-porphyrin (see Example 33).
- Example 41 above from 5-[4-(12-hydroxy-dodecyloxy)-phenyl]-10, 15,20- tris-(3,4,5-trihexadecyloxy-phenyl)-porphyrin (see Example 34).
- Example 41 above from 5-[4-(12-hydroxy-dodecyloxy)-phenyl]-10, 15,20- tris-(3,5-dihexyloxy-phenyl)-porphyrin (see Example 37).
- the tide compound was prepared according to the method described in
- Example 41 above from 5-[4-(12-hydroxy-dodecyloxy)-phenyl]-10, 15,20- tris-(3,5-dihexadecyloxy-phenyl)-porphyrin (see Example 40).
- Analytical grade potassium hydroxide (lOOg) was dissolved in Millipore ® water (lOOml) and the solution was made up to 250ml with Distol grade methanol.
- Gold deposition A layer of gold (ca. 45nm) was deposited on the slides using an Edwards 306 vacuum evaporator. A thin layer of chromium (ca. lnm) was initially deposited on the slides prior to the deposition of the gold to improve the adhesion of the gold to the slide.
- Procedure 1 Components for MED-6640 film preparation were obtained from Nusil Technology-Europe. Solution A (1.05ml) and solution B (1ml) were mixed with stirring. The solution of the respective po ⁇ hyrin of Examples 69 to 81 (see above) in xylene (50 ⁇ l) was added. Portions of the mixtore were deposited onto microscope cover slips (13mm diameter) which were placed in an oven and heated to 40 °C for 2hrs. The temperatore was gradually raised to 150°C and the slides were kept at this temperatore for 15mins and then allowed to cool.
- Procedure 2 The procedure 1 was repeated using solution A (1.025ml), solution B (1ml) and the solution of the respective po ⁇ hyrin in xylene (25 ⁇ l).
- TPP meso-tetraphenylpo ⁇ hyrin
- Zn TPP zinc tetraphenylpo ⁇ hyrin
- the fluorescence quantom yield for each of the title compounds of Examples 67 to 81 are listed in Table 1; values for Zn TPP and Mg TPP are included in Table 1 for reference but they were not measured in this work. Table 1. Fluorescence Quantum Yields
- a stock solution of each of the title compounds of Examples 67 to 81 was prepared by dissolving a small sample of the respective title compound in approximately 5ml of toluene (Fisher Scientific, Analytical grade). The exact concentrations of the stock solution was not dete ⁇ nined.
- a working solution of each of the title compounds of Examples 67 to 81 was prepared by diluting the respective stock solution with toluene to give an absorbance of 0.100 ⁇ 0.005 at 355nm when placed in a ultraviolet/visible spectrometer (ATI-Unicam UV-2) compared to a reference cell containing the pure toluene solvent.
- the ultraviolet/visible spectrum of each sample was also recorded over the range 300-700nm.
- the final concentration of each of the respective working solutions was estimated by reference to the determined UV extinction coefficient; each working solution had a concentration in the range 5-10 ⁇ mol dm "3 .
- a plot of A versus the incident laser energy was drawn for each sample and the slope deteraiined.
- the slope of such a graph is proportional to the singlet oxygen quantom yield.
- An example of a plot showing the linear relationship between the singlet oxygen emission intensity and the laser energy for the title compound of Example 78 and meso- tetraphenylpo ⁇ hyrin (TPP) is shown in Figure 3.
- the experiments were carried out using batches of 5 samples of the working solution of each of the title compounds of 67 to 81 plus one reference sample meso-tetraphenylpo ⁇ hyrin (TPP). Each run was repeated at least once. The data sets obtained for each sample were within ⁇ 5 % of the mean value.
- the dominant sources of error in the experiment include the shot-to-shot fluctuations in the laser and the difference in absorbances of the samples at the excitation wavelength.
- the values have an error of ⁇ 10% .
- the photosensitizable mixtore described above was deposited on a balloon shaped glass former and placed in an oven and heated to 40 °C for 2 hours.
- the temperatore was gradually raised to 150°C, maintained at 150°C for 15 minutes and then allowed to cool.
- the balloon was removed from the former, and the neck and the inflation port of the balloon adapted for engagement with a catheter.
- a standard silicon based polymeric catheter balloon was sprayed coated with the photosensitizable mixtore described above.
- the coating was cured as described in Procedure 1 to form a balloon having a molecular monolayer coating of the photosensitizable compound.
- a polymeric intraocular lens was spray coated with the photosensitizable mixture of Example 86 above and the coating cured as described in Example 86 to form an intraocular lens having a molecular monolayer coating of the photosensitizable compound.
- a polymeric vascular stent was spray coated with the photosensitizable mixture of Example 86 above and the coating cured as described in Example 86 to form a stent having a molecular monolayer coating of the photosensitizable compound.
- a layer of gold (approximately 45 nm) was deposited on a metallic vascular stent using an Edwards 306 vacuum evaporator.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99943075A EP1107971B1 (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
AU56360/99A AU765509B2 (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
US09/786,139 US6630128B1 (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives their use in photodynamic therapy and medical devices containing them |
AT99943075T ATE283271T1 (en) | 1998-08-28 | 1999-08-31 | PORPHYRIN DERIVATIVES, THEIR USE IN PHOTODYNAMIC THERAPY AND MEDICAL DEVICES CONTAINING THEM |
CA2341507A CA2341507C (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
JP2000567534A JP5008793B2 (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
DE69922216T DE69922216T2 (en) | 1998-08-28 | 1999-08-31 | PORPHYRINE DERIVATIVES, THEIR USE IN PHOTODYNAMIC THERAPY AND MEDICAL DEVICES CONTAINING THEREOF |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9818789.1 | 1998-08-28 | ||
GBGB9818789.1A GB9818789D0 (en) | 1998-08-28 | 1998-08-28 | Medical device |
GB9912971.0 | 1999-06-04 | ||
GBGB9912971.0A GB9912971D0 (en) | 1999-06-04 | 1999-06-04 | Medical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000012512A1 true WO2000012512A1 (en) | 2000-03-09 |
Family
ID=26314278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/002864 WO2000012512A1 (en) | 1998-08-28 | 1999-08-31 | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
Country Status (9)
Country | Link |
---|---|
US (1) | US6630128B1 (en) |
EP (1) | EP1107971B1 (en) |
JP (1) | JP5008793B2 (en) |
AT (1) | ATE283271T1 (en) |
AU (1) | AU765509B2 (en) |
CA (1) | CA2341507C (en) |
DE (1) | DE69922216T2 (en) |
ES (1) | ES2237146T3 (en) |
WO (1) | WO2000012512A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000765A1 (en) * | 2004-06-23 | 2006-01-05 | Destiny Pharma Limited | Novel uses |
US7244841B2 (en) | 2002-12-23 | 2007-07-17 | Destiny Pharma Limited | Porphyrin derivatives and their use in photodynamic therapy |
WO2007088392A1 (en) * | 2006-02-03 | 2007-08-09 | The Queen's University Of Belfast | Material and uses thereof |
EP2004197A2 (en) * | 2006-03-31 | 2008-12-24 | North Carolina State University | Light activated antiviral materials and devices and methods for decontaminating virus infected environments |
EP2253634A1 (en) * | 2008-03-11 | 2010-11-24 | Dai Nippon Printing Co., Ltd. | Liquid porphyrin derivative and method for producing the same |
US8658433B2 (en) | 2000-01-18 | 2014-02-25 | Mallinckrodt Llc | Dye compounds as photoactive agents |
US9216272B2 (en) | 2002-09-20 | 2015-12-22 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US10551637B2 (en) | 2006-03-20 | 2020-02-04 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
WO2021007638A1 (en) * | 2019-07-16 | 2021-01-21 | Universidade De São Paulo - Usp | Method for obtaining functionalized polymeric surfaces with photosensitizers, functionalized polymeric material and use thereof |
WO2022074014A1 (en) * | 2020-10-05 | 2022-04-14 | Biolitec Unternehmensbeteiligungs Ii Ag | Tetrapyrrole-based compounds and their formulations for anti-microbial therapy |
US11701315B2 (en) | 2006-03-20 | 2023-07-18 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US11925686B2 (en) | 2015-07-23 | 2024-03-12 | Eyebright Medical Technology (Beijing) Co., Ltd. | Materials for phototherapies of ophthalmic diseases |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050255039A1 (en) * | 1998-06-26 | 2005-11-17 | Pro Surg, Inc., A California Corporation | Gel injection treatment of breast, fibroids & endometrial ablation |
US6545102B1 (en) * | 2001-09-27 | 2003-04-08 | Lumigen, Inc. | Polymer-supported photosensitizers |
US6962910B2 (en) * | 2002-02-01 | 2005-11-08 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photoactivated DNA cleavage agents |
ITFI20020200A1 (en) * | 2002-10-21 | 2004-04-22 | Molteni & C Dei Flii Alitti S P A Societa L | MESO-REPLACED PORPHYRINES. |
US7008937B2 (en) * | 2003-06-10 | 2006-03-07 | Frontier Scientific, Inc. | Porphyrins and metalloporphyrins for inhibiting heme iron uptake |
ITFI20050092A1 (en) * | 2005-05-05 | 2006-11-06 | Molteni & C | PHYTALOCIANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE |
ITFI20050093A1 (en) * | 2005-05-05 | 2006-11-06 | Molteni & C | PROCESS FOR THE PREPARATION OF CHLORIDE OF PHYTALOCYANIC DERIVATIVES INCLUDING AT LEAST A AMMONIUM QUATERNARY GROUP |
PL1904109T3 (en) * | 2005-06-29 | 2013-09-30 | Molteni Therapeutics S R L | Self-sterilizing products |
US20090123516A1 (en) * | 2005-08-08 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Drug delivery from implants using self-assembled monolayers-therapeutic sams |
EP2361549A3 (en) * | 2005-09-30 | 2012-05-02 | Cornova, Inc. | System for analysis and treatment of a body lumen |
WO2009089372A2 (en) * | 2008-01-08 | 2009-07-16 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
AU2007325483B2 (en) * | 2006-11-28 | 2013-08-29 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US20090318370A1 (en) * | 2007-02-19 | 2009-12-24 | Rei Medical Co., Ltd. | Novel glycoconjugated chlorin derivatives and method of producing the same |
MX2010006972A (en) | 2007-12-21 | 2010-08-26 | Ligand Pharm Inc | Selective androgen receptor modulators (sarms) and uses thereof. |
EP2250181A1 (en) * | 2008-02-08 | 2010-11-17 | Binyomin A. Cohen | Ruthenium compounds and compositions |
EP2432542A4 (en) * | 2009-05-20 | 2013-07-03 | Cornova Inc | Systems and methods for analysis and treatment of a body lumen |
US8203118B2 (en) * | 2009-12-11 | 2012-06-19 | Honeywell International, Inc. | Ion-trap mass spectrometer driven by a monolithic photodiode array |
DE102010001757A1 (en) * | 2010-02-10 | 2011-08-11 | Technische Universität Graz | Antibiofouling coating, useful e.g. for coating an article and surface of sensors, preferably optical sensors, sensors for process control or environmental sensors, comprises a dye generating singlet oxygen, immobilized in and/or on matrix |
WO2012029609A1 (en) * | 2010-09-02 | 2012-03-08 | 国立大学法人 群馬大学 | Compound having silicon-containing substituent introduced thereto, and singlet oxygen-generating agent and cancer therapeutic comprising same |
US9126890B2 (en) * | 2011-10-20 | 2015-09-08 | International Flavors & Fragrances Inc. | Low volatile reactive malodor counteractives and methods of use thereof |
US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
JP6663841B2 (en) * | 2013-03-15 | 2020-03-13 | ブリット,エドワード,ジェー. | Energy conversion device and method of making and using the same |
CN104863554A (en) * | 2014-02-26 | 2015-08-26 | 中国石油天然气股份有限公司 | Profile control agent for super heavy oil well and application |
CN106773120A (en) * | 2015-11-25 | 2017-05-31 | 鸿富锦精密工业(深圳)有限公司 | Contact lens material and contact lens |
WO2018053316A1 (en) | 2016-09-15 | 2018-03-22 | The Regents Of The University Of California | Improved hybrid telodendrimers |
KR102179530B1 (en) * | 2018-12-27 | 2020-11-18 | 서울대학교산학협력단 | Self-assembled nanoparticles comprising photosensitizer and composition for using photodynamic therapy comprising the same |
US20210169549A1 (en) * | 2019-12-04 | 2021-06-10 | Acclarent, Inc. | Photodynamic therapy ablation device |
JP6886578B1 (en) | 2020-09-01 | 2021-06-16 | 株式会社エム・ティー・スリー | Compounds or salts thereof, cancer therapeutic agents, photosensitizers, and fluorescent probe compositions |
KR102664860B1 (en) * | 2021-06-22 | 2024-05-10 | 주식회사 에스앤지바이오텍 | Photo-responsive fundic stent |
KR102605175B1 (en) * | 2021-06-22 | 2023-11-24 | 주식회사 에스앤지바이오텍 | Photo-responsive duodenum stent |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05247081A (en) * | 1991-08-05 | 1993-09-24 | Honen Corp | New tetraphenyulporphyrin glycoside and its production |
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5594136A (en) * | 1989-12-21 | 1997-01-14 | Pharmacyclics, Inc. | Texaphyrin solid supports and devices |
DE19627164A1 (en) * | 1996-07-05 | 1998-01-08 | Deutsches Krebsforsch | Production of chlorine and bacteriochlorine containing polyethers |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4512762A (en) | 1982-11-23 | 1985-04-23 | The Beth Israel Hospital Association | Method of treatment of atherosclerosis and a balloon catheter for same |
GB8429845D0 (en) * | 1984-11-26 | 1985-01-03 | Efamol Ltd | Porphyrins & cancer treatment |
SE8505518D0 (en) * | 1985-11-22 | 1985-11-22 | Swedish Graft Tech Ab | IMPLANTATION LENS, PROCEDURE FOR PREPARING THEREOF AND APPARATUS FOR CARRYING OUT THE PROCEDURE |
US5051415A (en) | 1986-01-02 | 1991-09-24 | The University Of Toledo | Production and use of purpurins, chlorins and purpurin- and chlorin-containing compositions |
JPS636451A (en) | 1986-06-27 | 1988-01-12 | Terumo Corp | Enzyme sensor |
US4812352A (en) | 1986-08-25 | 1989-03-14 | Minnesota Mining And Manufacturing Company | Article having surface layer of uniformly oriented, crystalline, organic microstructures |
US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
JP2613647B2 (en) | 1987-02-13 | 1997-05-28 | イギリス国 | Substituted phthalocyanines |
SU1553537A1 (en) | 1988-03-04 | 1990-03-30 | Сыктывкарский Государственный Университет Им.50-Летия Ссср | Method of producing water-soluble copolymers of metalloporphyrins |
GB8805849D0 (en) * | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
SU1684289A1 (en) | 1988-08-16 | 1991-10-15 | Институт Биологической И Медицинской Химии Амн Ссср | Method preparation of conjugates on the basis of sepharose derivative |
JP2575199B2 (en) | 1988-11-25 | 1997-01-22 | 株式会社トクヤマ | Method for producing carbonate copolymer |
JP2738943B2 (en) | 1988-12-27 | 1998-04-08 | 株式会社長野計器製作所 | Polymer complex for oxygen adsorbent |
JP2763612B2 (en) | 1989-09-08 | 1998-06-11 | 株式会社トクヤマ | Porphyrin derivative having polymerizable group and method for producing the same |
US5457195A (en) | 1989-12-21 | 1995-10-10 | Board Of Regents, The University Of Texas System | Sapphyrin derivatives and conjugates |
US5159065A (en) | 1989-12-21 | 1992-10-27 | Board Of Regents, The University Of Texas System | Sapphyrins, derivatives and syntheses |
US5543514A (en) | 1989-12-21 | 1996-08-06 | Board Of Regents, The University Of Texas System | Water-soluble sapphyrins |
US5053423A (en) | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
GB9007408D0 (en) | 1990-04-02 | 1990-05-30 | Nycomed As | Compositions |
WO1991018006A1 (en) | 1990-05-15 | 1991-11-28 | Diatron Corporation | Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
DE69132744T2 (en) | 1990-05-15 | 2002-10-10 | Hyperion, Inc. | Detectably labeled marker compound with a fluorophore residue, a fluorescence sample with the marker compound and uses thereof. |
ATE115864T1 (en) | 1990-05-30 | 1995-01-15 | Deutsches Krebsforsch | POLYETHER-SUBSTITUTED TUMOR AGENTS. |
US5622685A (en) | 1990-05-30 | 1997-04-22 | Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts | Polyether-substituted porphyrin anti-tumor agents |
JPH0657307B2 (en) | 1990-06-30 | 1994-08-03 | ユニオン・カーバイド・インダストリアル・ガセズ・テクノロジー・コーポレーション | Oxygen-permeable polymer membrane |
JPH0657308B2 (en) | 1990-08-15 | 1994-08-03 | ユニオン・カーバイド・インダストリアル・ガセズ・テクノロジー・コーポレーション | Oxygen separation porous membrane |
EP0484027B1 (en) | 1990-11-02 | 1996-12-18 | Zeneca Limited | Polysubstituted phthalocyanines |
US5411580A (en) | 1991-07-31 | 1995-05-02 | Praxair Technology, Inc. | Oxygen-separating porous membranes |
WO1993003776A1 (en) * | 1991-08-16 | 1993-03-04 | Galin Miles A | Medicament coated refractive anterior chamber ocular implant |
US5371199B1 (en) | 1992-08-14 | 1995-12-26 | Univ Pennsylvania | Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor |
US5783306A (en) | 1992-08-14 | 1998-07-21 | Trustees Of The University Of Pennsylvania | Hyperpolarizable compounds and devices fabricated therefrom |
US5599924A (en) | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
WO1994004507A1 (en) | 1992-08-21 | 1994-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Basket porphyrin oxygen carriers |
DE4305523A1 (en) | 1993-02-17 | 1994-08-18 | Diagnostikforschung Inst | Meso-tetraphenylporphyrin complexes, processes for their preparation and pharmaceutical compositions containing them |
GB9317881D0 (en) | 1993-08-27 | 1993-10-13 | Secr Defence | Photosensitizers |
US5994339A (en) | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
EP0741547B1 (en) * | 1994-01-26 | 2005-04-20 | Kyphon Inc. | Improved inflatable device for use in surgical protocol relating to fixation of bone |
US5707986A (en) | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
WO1995029702A1 (en) | 1994-04-28 | 1995-11-09 | Board Of Regents, The University Of Texas System | Texaphyrin solid-supports and devices |
GB9408746D0 (en) | 1994-05-03 | 1994-06-22 | Scotia Holdings Plc | Tumour locallising photosensitising compounds |
US5697973A (en) | 1994-09-19 | 1997-12-16 | Peyman; Gholam A. | Intraocular silicone lens |
ES2249784T3 (en) | 1995-06-07 | 2006-04-01 | Duke University | ANTIOXIDANTGES OF OXIDANTS. |
WO1997015661A1 (en) | 1995-10-25 | 1997-05-01 | Eoe, Inc. | Microporous pathogen-killing composition |
GB9524028D0 (en) | 1995-11-23 | 1996-01-24 | Secr Defence | Substituted porphyrins |
US5776138A (en) | 1996-01-26 | 1998-07-07 | Allergan | Apparatus and methods for IOL insertion |
NO304735B1 (en) | 1996-02-07 | 1999-02-08 | Singlet Oxygen Technologies As | Apparatus for providing a singlet oxygen-activated oxygen-containing gas stream |
US5716364A (en) | 1996-07-10 | 1998-02-10 | Allergan | IOL insertion apparatus and method for making and using same |
US6043237A (en) | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
EP0968013B1 (en) * | 1997-02-20 | 2005-10-19 | Cook Incorporated | Coated implantable medical device |
-
1999
- 1999-08-31 AT AT99943075T patent/ATE283271T1/en not_active IP Right Cessation
- 1999-08-31 WO PCT/GB1999/002864 patent/WO2000012512A1/en active IP Right Grant
- 1999-08-31 US US09/786,139 patent/US6630128B1/en not_active Expired - Fee Related
- 1999-08-31 EP EP99943075A patent/EP1107971B1/en not_active Expired - Lifetime
- 1999-08-31 JP JP2000567534A patent/JP5008793B2/en not_active Expired - Fee Related
- 1999-08-31 AU AU56360/99A patent/AU765509B2/en not_active Ceased
- 1999-08-31 ES ES99943075T patent/ES2237146T3/en not_active Expired - Lifetime
- 1999-08-31 DE DE69922216T patent/DE69922216T2/en not_active Expired - Lifetime
- 1999-08-31 CA CA2341507A patent/CA2341507C/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5594136A (en) * | 1989-12-21 | 1997-01-14 | Pharmacyclics, Inc. | Texaphyrin solid supports and devices |
JPH05247081A (en) * | 1991-08-05 | 1993-09-24 | Honen Corp | New tetraphenyulporphyrin glycoside and its production |
DE19627164A1 (en) * | 1996-07-05 | 1998-01-08 | Deutsches Krebsforsch | Production of chlorine and bacteriochlorine containing polyethers |
Non-Patent Citations (14)
Title |
---|
C. LATOUCHE. ET. AL.: "Synthesis of Porphyrins with Pendant Arms. Participation of the Ancillary Ligands to the Complexation Process in Proteic Medium.", TETRAHEDRON LETTERS, vol. 36, no. 10, 1995, pages 1665 - 6, XP004028558 * |
DATABASE WPI Week 9343, Derwent World Patents Index; AN 1993-339745, XP002125263 * |
G. MEHTA ET. AL.: "Porphyrin Anthraquinone Hybrids. Wavelength Dependent DNA Photonucleases.", TETRAHEDRON LETTERS, vol. 38, no. 40, 1997, pages 7125 - 8, XP004090436 * |
G. MEHTA ET. AL.: "Porphyrin-Chlorambucil Conjugates: Synthesis and Light Induced Nuclease Activity.", TETRAHEDRON LETTERS, vol. 35, no. 24, 1994, pages 4201 - 4, XP002125261 * |
G. MEHTA ET. AL.: "Synthesis and Nuclease Activity of Some Porphyrin Acridone Hybrid Molecules", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANS. 1, no. 22, November 1993 (1993-11-01), pages 2667 - 9, XP002125260 * |
G.A. ZHAMKOCHYAN ET. AL.: "Synthesis of new unsaturated mesotetraarylporphyrins.", CHEMISTRY OF HETEROCYCLIC COMPOUNDS (ENGLISH TRANSLATION), vol. 23, - 1987, pages 186-191, XP002125252 * |
H-J SCHNEIDER ET. AL.: "DNA Interactions with Porphyrins Bearing ammonium Side Chains", JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 24, 2 December 1994 (1994-12-02), pages 7473 - 8, XP002125258 * |
J. S. LINDSEY ET. AL.: "Rothemund and Adler-Longo Reactions Revisited. Synthesis of Tetraphenylporphyrins under Equilibrium Conditions.", JOURNAL OF ORGANIC CHEMISTRY, vol. 52, no. 5, 6 March 1987 (1987-03-06), pages 827 - 36, XP002125259 * |
J. S. MANKA ET. AL.: "Template Driven Self Assembly of a Porphyrin Containing Supramolecular Complex.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 112, no. 6, 14 March 1990 (1990-03-14), pages 2440 - 2, XP002125256 * |
J. W. BUCHLER ET. AL.: "Cerium(IV) Sandwich Complexes with Porphyrin Ligands Linked by Aliphatic Quinone containing Bridges.", CHEMISCHE BERICHTE, vol. 129, no. 9, September 1996 (1996-09-01), pages 1073 - 81, XP002125255 * |
L. R. MILGROM: "Synthesis of some New tetraarylporphyrins for Studies in Solar Energy Conversion.", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANS. 1, no. 10, 1983, pages 2535 - 9, XP002125257 * |
R. G. LITTLE ET. AL.: "The Synthesis of Covalently Linked Tetraarylporphyrin Dimers", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 15, no. 2, March 1978 (1978-03-01), pages 203 - 8, XP002125262 * |
S. A. SYRBU ET. AL.: "Synthesis of tetraphenylporphines with active groups in the phenyl rings. Tetra(carboxymethyleneoxyphenyl) porphines and their ethyl esters.", CHEMISTRY OF HETEROCYCLIC COMPOUNDS (ENGLISH TRANSLATION), vol. 25, 1989, pages 1149 - 53, XP002125254 * |
S. A. SYRBU ET. AL.: "Synthesis of tetraphenylporphyrins with active groups in the phenyl rings. 4. Functionally substituted monohydroxy derivatives of tetraphenylporphine.", CHEMISTRY OF HETEROCYCLIC COMPOUNDS (ENGLISH TRANSLATION), vol. 23, 1987, pages 645 - 50, XP002125253 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8658433B2 (en) | 2000-01-18 | 2014-02-25 | Mallinckrodt Llc | Dye compounds as photoactive agents |
US9687635B2 (en) | 2002-09-20 | 2017-06-27 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US9302080B2 (en) | 2002-09-20 | 2016-04-05 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US9216273B2 (en) | 2002-09-20 | 2015-12-22 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US9216272B2 (en) | 2002-09-20 | 2015-12-22 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US7244841B2 (en) | 2002-12-23 | 2007-07-17 | Destiny Pharma Limited | Porphyrin derivatives and their use in photodynamic therapy |
US8084602B2 (en) * | 2002-12-23 | 2011-12-27 | Destiny Pharma Limited | Porphyrin derivatives and their use in photodynamic therapy |
KR101380229B1 (en) | 2004-06-23 | 2014-04-11 | 데스티니 파르마 리미티드 | Novel uses |
NO338010B1 (en) * | 2004-06-23 | 2016-07-18 | Destiny Pharma Ltd | New uses of porphyrin compounds |
WO2006000765A1 (en) * | 2004-06-23 | 2006-01-05 | Destiny Pharma Limited | Novel uses |
US8450359B2 (en) | 2006-02-03 | 2013-05-28 | The Queen's University Of Belfast | Polymer-supported photosensitizers for the generation of singlet oxygen |
AU2007210947B2 (en) * | 2006-02-03 | 2012-12-13 | The Queen's University Of Belfast | Material and uses thereof |
WO2007088392A1 (en) * | 2006-02-03 | 2007-08-09 | The Queen's University Of Belfast | Material and uses thereof |
US11701315B2 (en) | 2006-03-20 | 2023-07-18 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US11774783B2 (en) | 2006-03-20 | 2023-10-03 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US10551637B2 (en) | 2006-03-20 | 2020-02-04 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
AU2006341380B2 (en) * | 2006-03-31 | 2013-01-10 | Emory University | Light activated antiviral materials and devices and methods for decontaminating virus infected environments |
EP2004197A4 (en) * | 2006-03-31 | 2009-08-19 | Univ North Carolina State | Light activated antiviral materials and devices and methods for decontaminating virus infected environments |
EP2004197A2 (en) * | 2006-03-31 | 2008-12-24 | North Carolina State University | Light activated antiviral materials and devices and methods for decontaminating virus infected environments |
EP2253634A1 (en) * | 2008-03-11 | 2010-11-24 | Dai Nippon Printing Co., Ltd. | Liquid porphyrin derivative and method for producing the same |
EP2253634A4 (en) * | 2008-03-11 | 2012-03-21 | Dainippon Printing Co Ltd | Liquid porphyrin derivative and method for producing the same |
US11925686B2 (en) | 2015-07-23 | 2024-03-12 | Eyebright Medical Technology (Beijing) Co., Ltd. | Materials for phototherapies of ophthalmic diseases |
CN114126695A (en) * | 2019-07-16 | 2022-03-01 | 巴西圣保罗大学 | Method for obtaining functionalized polymer surfaces with photosensitizers, functionalized polymer materials and uses thereof |
WO2021007638A1 (en) * | 2019-07-16 | 2021-01-21 | Universidade De São Paulo - Usp | Method for obtaining functionalized polymeric surfaces with photosensitizers, functionalized polymeric material and use thereof |
WO2022074014A1 (en) * | 2020-10-05 | 2022-04-14 | Biolitec Unternehmensbeteiligungs Ii Ag | Tetrapyrrole-based compounds and their formulations for anti-microbial therapy |
Also Published As
Publication number | Publication date |
---|---|
JP2002523509A (en) | 2002-07-30 |
DE69922216T2 (en) | 2005-12-01 |
US6630128B1 (en) | 2003-10-07 |
DE69922216D1 (en) | 2004-12-30 |
ES2237146T3 (en) | 2005-07-16 |
JP5008793B2 (en) | 2012-08-22 |
AU5636099A (en) | 2000-03-21 |
EP1107971B1 (en) | 2004-11-24 |
AU765509B2 (en) | 2003-09-18 |
CA2341507A1 (en) | 2000-03-09 |
EP1107971A1 (en) | 2001-06-20 |
CA2341507C (en) | 2011-05-24 |
ATE283271T1 (en) | 2004-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1107971B1 (en) | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them | |
US5591847A (en) | Long wavelength absorbing photosensitizers related to purpurin-18, bacteriopurpurin-18 and related compounds with imide linkages | |
DK168296B1 (en) | Fluorescent mono-, di- or polyamides of an amino-monocarboxylic acid and a tetrapyrrole compound and their use in the preparation of a pharmaceutical composition for photodiagnosis and / or phototherapy of tumors | |
JP5555659B2 (en) | Water-soluble anionic bacteriochlorophyll derivatives and their use | |
KR101288460B1 (en) | Photosensitizer comprising quantum dot-chlorin derivative conjugate, and a composition for treatment and diagnosis of cancer for using in photodynamic therapy comprising the same | |
WO2011089509A1 (en) | A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes | |
US20030148926A1 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
HU223379B1 (en) | Synthetic metal-substituted bacteriochlorophyll derivatives and use thereof | |
CN103059184B (en) | Amino porphyrin- poly (N-isopropylacrylamide) europium coordination compound and preparation method thereof | |
EP0644759A4 (en) | Production and use of imines of porphyrins. | |
EP1263761A2 (en) | Compounds for pdt | |
US8664392B2 (en) | Pyrazine derivatives for bioconjugation | |
WO2014011370A1 (en) | Tetrapyrollic photosensitizers for conjugation with paa nanop articles for tumor treatment and imaging | |
KR20070036152A (en) | Adduct of fluorescent dye and tumor avid tetrapyrrole | |
Reshetnickov et al. | Novel drug form of chlorin e6 | |
Ol'shevskaya et al. | Boronated protohaemins: synthesis and in vivo antitumour efficacy | |
Grin et al. | Novel bacteriochlorophyll-based photosensitizers and their photodynamic activity | |
CN106924732A (en) | A kind of ultrasonic therapy cancer target type haematoporphyrin injection and preparation method thereof | |
KR101847486B1 (en) | Porphyrin derivative having hydrophilic group and hydrophobic group, and process for preparing the same | |
CN112533634B (en) | hypericin-PVP compound with high hypericin content | |
RU2521327C1 (en) | Preparation for photodynamic therapy and method for photodynamic therapy of cancer with using it | |
US7449454B2 (en) | Metallotexaphyrin derivatives | |
Faiza et al. | PHOTODYNAMIC EFFECT OF NEW PORPHYRIN DERIVATIVE FOR CANCER TREATMENT | |
WO2008018063A2 (en) | Tetraarylporphine derivatives and uses thereof | |
Helmreich | Crown Ether-Metalloporphyrins as Ditopic Receptors and Pyropheophorbide-a Conjugates for the Photodynamic Therapy of Tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 56360/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2341507 Country of ref document: CA Ref country code: CA Ref document number: 2341507 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 567534 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999943075 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09786139 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999943075 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 56360/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999943075 Country of ref document: EP |